Ozmosi | Admilparant Drug Profile

Product Description

Admilparant (BMS-986278) is an oral lysophosphatidic acid receptor 1 antagonist, in patients with IPF and PPF. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/39393084/)

Mechanisms of Action: LPAR1 Antagonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: Breakthrough Therapy - Pulmonary Fibrosis|Progressive Pulmonary Fibrosis *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Bristol-Myers Squibb
Company Location: Eastern America
Company CEO: Giovanni Caforio
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Admilparant

Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, India, Ireland, Israel, Italy, Japan, Korea, Malaysia, Mexico, Netherlands, Peru, Poland, Portugal, Puerto Rico, South Korea, Spain, Sweden, Switzerland, Taiwan, United Kingdom, United States, Unknown Location

Active Clinical Trial Count: 21

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Pulmonary Fibrosis

Phase 1: Healthy Volunteers|Kidney Failure, Chronic

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success	Latest Trial Update Date	Data Updated
NCT05985590	IM027-1013	P1	Completed	Pulmonary Fibrosis	2023-12-11	23%	2024-01-25	Primary Endpoints
NCT06025578	IM027-1015	P3	Active, not recruiting	Scleroderma, Diffuse\|Sarcoidosis, Pulmonary\|Progressive Pulmonary Fibrosis\|Arthritis, Rheumatoid\|Lung Diseases, Interstitial	2027-12-27	52%	2025-12-18	Primary Endpoints\|Treatments\|Trial Status
NCT06003426	IM027-068	P3	Active, not recruiting	Idiopathic Pulmonary Fibrosis	2026-10-26	73%	2025-09-30	Primary Endpoints
NCT06723535	IM027-1014	P1	Completed	Kidney Failure, Chronic	2025-09-16	50%	2025-10-15
NCT06568458	IM027-1026	P1	Completed	Healthy Volunteers	2025-02-27	50%	2025-03-18
NCT06425198	IM027-1009	P1	Completed	Healthy Volunteers	2024-12-30	88%	2025-01-23	Patient Enrollment\|Primary Completion Date\|Primary Endpoints\|Start Date\|Study Completion Date\|Treatments\|Trial Status
NCT05932303	IM027-1007	P1	Completed	Idiopathic Pulmonary Fibrosis	2023-10-23	23%	2023-10-31	Patient Enrollment\|Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments\|Trial Status
NCT05805904	IM027-067	P1	Completed	Healthy Volunteers	2023-05-23	23%	2023-09-19	Primary Completion Date\|Primary Endpoints\|Study Completion Date
CTR20230295	CTR20230295	P1	Completed	Idiopathic Pulmonary Fibrosis	2023-05-23		2025-04-29
NCT05684289	IM027-1017	P1	Completed	Idiopathic Pulmonary Fibrosis	2023-05-02	69%	2023-08-25	Primary Completion Date\|Primary Endpoints
jRCT2080225297	jRCT2080225297	P2	Completed	Pulmonary Fibrosis	2024-02-29
2019-003992-21	Phase 2 Study of the Efficacy and Safety of BMS-986278 in Pulmonary Fibrosis	P2	Completed	Pulmonary Fibrosis	2023-09-22	3%	2025-06-08	Treatments
JapicCTI-205393	JapicCTI-205393	P2	Planned	Pulmonary Fibrosis	2023-03-31
CTR20213153	CTR20213153	P2	Active, not recruiting	Pulmonary Fibrosis	None		2025-04-29	Patient Enrollment\|Start Date\|Treatments\|Trial Status
jRCT2021230037	jRCT2021230037	P3	Recruiting	Progressive Pulmonary Fibrosis	2027-09-02
jRCT2021230026	jRCT2021230026	P3	Recruiting	Idiopathic Pulmonary Fibrosis	2027-12-03
2023-503697-21-01	IM027068	P3	Recruiting	Idiopathic Pulmonary Fibrosis	2026-10-26		2025-05-02	Treatments
2023-503699-25-00	IM0271015	P3	Recruiting	Progressive Pulmonary Fibrosis	2026-10-26		2025-05-02	Treatments
NCT07225647	IM027-1052	P1	Recruiting	Healthy Volunteers	2025-12-28	88%	2025-12-11	Primary Endpoints
NCT06746402	IM027-1012	P1	Completed	Healthy Volunteers	2025-09-11	50%	2025-10-07
NCT06715683	IM027-1035	P1	Completed	Healthy Volunteers	2025-03-16	88%	2025-04-05	Primary Endpoints\|Treatments\|Trial Status

Recent News Events

Date	Type	Title
06/17/2025	News Article	Pulmonologists and Rheumatologists Struggle to Diagnose and Manage CTD-ILD, According to New Research from Spherix Global Insights
02/13/2024	PubMed	Peroxygenase-Catalyzed Allylic Oxidation Unlocks Telescoped Synthesis of (1S,3R)-3-Hydroxycyclohexanecarbonitrile.
10/26/2023	News Article	Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
09/14/2023	News Article	Bristol Myers Squibb Highlights Advancing Pipeline and Differentiated Research Platforms to Support Long-Term Sustainable Growth at R&D Day
09/09/2023	News Article	Bristol Myers Squibb's Investigational LPA1 Antagonist Reduces Rate of Lung Function Decline in Progressive Pulmonary Fibrosis Cohort of Phase 2 Study
03/01/2022	PubMed	Mechanism of hepatobiliary toxicity of the LPA(1) antagonist BMS-986020 developed to treat idiopathic pulmonary fibrosis: Contrasts with BMS-986234 and BMS-986278.
03/01/2022	PubMed	Structure dependence and species sensitivity of in vivo hepatobiliary toxicity with lysophosphatidic acid receptor 1 (LPA1) antagonists.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

Admilparant

Alternative Names: Admilparant, bms-986278, bms986278, bms 986278 Clinical Status: Active Latest Update: 2025-12-17 Latest Update Note: Clinical Trial Update